The supplementary materials report increases in revenue and operating income following the transition to a two-segment structure. Both Pharmaceuticals and Chemicals saw revenue growth, while improvements in cost of goods sold and reductions in selling, general and administrative expenses drove overall profit increases. The second-quarter earnings forecast was revised, while the full-year forecast remains unchanged. The company plans to strengthen technical capabilities through initiatives such as establishing a Chemicals Development Center.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4885","jir_company_name":"Muromachi Chemicals Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4885-20261015-03.pdf","jir_short_summary":"The supplementary materials report increases in revenue and operating income following the transition to a two-segment structure. Both Pharmaceuticals and Chemicals saw revenue growth, while improvements in cost of goods sold and reductions in selling, general and administrative expenses drove overall profit increases. The second-quarter earnings forecast was revised, while the full-year forecast remains unchanged. The company plans to strengthen technical capabilities through initiatives such as establishing a Chemicals Development Center.","jir_summary":"### Overview\nThe supplementary materials report that, as the initial results following the transition to a two-segment structure, both the Pharmaceuticals and Chemicals divisions achieved increases in revenue and operating income. Improvements in cost of goods sold and reductions in selling, general and administrative expenses expanded gross profit and operating income. The impact of withdrawing from the health foods business was absorbed, resulting in profitability at the consolidated level. As of the end of the first quarter of the fiscal year ending May 2027, the equity ratio improved by 5.1 percentage points, and total assets declined due to a decrease in current liabilities.\n\n### Outlook and Strategy\nFollowing the shift to a two-segment structure, the company expects to maintain revenue growth in both Pharmaceuticals and Chemicals. It will promote strengthening of technical capabilities through the establishment of a Chemicals Development Center and the creation of new products. Although the second-quarter earnings forecast was revised, the full-year forecast remains aligned with the prior outlook. Medium-term priorities include enhancing profitability by expanding imported active pharmaceutical ingredients and securing in-house manufacturing projects.","jir_financial_highlights":"Revenue: 1,861 million yen (Year-over-Year +4.1%)\nRevenue: 1,787 million yen (End of previous fiscal year)\nOperating Income: 182 million yen (Year-over-Year +108 million yen)\nOrdinary Income: 191 million yen (Year-over-Year +118 million yen)\nNet Income Attributable to Owners of Parent: 142 million yen (Year-over-Year +84 million yen)","jir_category":"","jir_hashtags":"#MUROMACHI_CHEMICALS, #Earnings, #BusinessStrategy","jir_key_figures":"Revenue: 1,861 million yen (Q1, Year-over-Year +4.1%)\nOperating Income: 182 million yen (Year-over-Year +108 million yen)\nOrdinary Income: 191 million yen (Year-over-Year +118 million yen)\nNet Income Attributable to Owners of Parent: 142 million yen (Year-over-Year +84 million yen)","jir_meta_title":"Muromachi Chemicals Inc. Supplementary Financial Presentation Materials | Q1 FY Ending May 2027","jir_meta_description":"Summary of Muromachi Chemicals Inc.'s supplementary financial presentation materials: post-transition revenue and profit trends, improvements in cost of goods sold, reductions in SG&A, and plans for developing a Chemicals Development Center and business strategy.","jir_og_title":"Muromachi Chemicals Inc. | Supplementary Financial Presentation Materials","jir_og_description":"Detailed description of performance after the transition to a two-segment structure, segment results, and growth strategies. Review the Pharmaceuticals and Chemicals growth and technical capability enhancement plans.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"[]\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"[]\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"[]\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"[]\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Forecast vs Actual Comparison\", \"jir_chart_json_data\": \"[]\"}]","ir_related_company":60599,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-131902","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n